COLUMBUS, Ohio and BOSTON, April 29, 2025 /PRNewswire/ -- Akita Biosciences, Inc., a consumer health company that develops innovative nasal spray formulations for drug, device, and cosmetic ...
Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported ...
ERM Japan and Ocean Energy Pathway (OEP) have published a comprehensive joint report that examines the gross value added (GVA) generated by offshore wind projects in Akita Prefecture, and assesses ...
The AKITA study is a randomized, double-blind, placebo-controlled Phase 2 study of RMC-035 in patients undergoing open-heart surgery and at increased risk to develop kidney injuries. A total of 177 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results